<DOC>
	<DOCNO>NCT00030901</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development cancer . The use selenium may effective way prevent prostate cancer patient neoplasia prostate . PURPOSE : Randomized phase III trial study effectiveness selenium prevent prostate cancer patient neoplasia prostate .</brief_summary>
	<brief_title>S9917 , Selenium Preventing Cancer Patients With Neoplasia Prostate</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect selenium versus placebo 3-year incidence rate prostate cancer patient high-grade prostatic intraepithelial neoplasia . - Compare toxicity regimens patient . - Compare effect regimens rate increase prostate-specific antigen ( PSA ) patient . - Compare effect regimens prostatic cellular proliferation apoptosis , degradation basal cell integrity prostatic duct , change nuclear chromatin pattern patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord age ( 40-60 v 61 ) , race ( African American v ) , baseline PSA ( less 4 ng/mL vs 4-10 ng/mL ) , concurrent vitamin E supplementation ( yes v ) , core obtain initial biopsy ( 10 v less 10 ) . Patients randomize 1 2 arm . - Arm I : Patients receive oral selenium daily . - Arm II : Patients receive oral placebo daily . Treatment arm continue 3 year absence progression prostate cancer unacceptable toxicity . Patients follow every 6 month 2 year annually 8 year . PROJECTED ACCRUAL : A total 465 patient randomize study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Prostatic Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis highgrade prostatic intraepithelial neoplasia evidence cancer Documented digital rectal exam biopsy prostate transrectal ultrasound guidance ( require few 6 core obtain biopsy ) meet one follow condition : Biopsy yield few 10 core within past 24 month OR yield 10 core 624 month study Biopsy yield 10 core within past 6 month PSA ≤ 10 ng/mL ( ≤ 5 ng/mL patient receive finasteride androgen suppressor within past 2 month ) American Urological Association symptom score less 20 PATIENT CHARACTERISTICS : Age : 40 Performance status : SWOG 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer adequately treat stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy See Disease Characteristics No concurrent finasteride androgen suppressor Radiotherapy Not specify Surgery Not specify Other At least 30 day since prior daily dietary supplement contain 50 microgram selenium No concurrent daily dietary supplement contain 50 microgram selenium</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>high grade prostatic intraepithelial neoplasia</keyword>
</DOC>